Helix BioPharma Corp. announces FDA approval to Accelerate

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
110
Helix BioPharma Corp. announces FDA approval to Accelerate Dose Escalation for U.S. Phase I Clinical Study

RICHMOND HILL, ONTARIO--(Marketwired - Sept. 27, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the U.S. Food and Drug Administration ("FDA") has approved an amendment to their U.S. Phase I study, protocol LDOS001, that will accelerate the dose escalation phase of the study.

In order to maximize the number of patients receiving a potentially active dose of L-DOS47, the study will implement an accelerated dose design up to 6µg/kg followed by a standard 3+3 design for the final two dosing cohorts, 9 and 12 µg/kg, respectively.

"This was a significant achievement in the advancement of the study," said Steve Demas, Chief Operating Officer of Helix. "We will be able to move more rapidly through the escalation phase to doses of L-DOS47 that exhibited the best patient responses in the Phase I monotherapy study ("LDOS002"), recently completed in Poland. We are also planning on opening additional centers to further accelerate the completion of the study."

The company provided an update to the LDOS001 study at the Biotech Showcase on January 10 th , 2017 in San Francisco. Highlights included the following:

  • No dose limiting toxicities reported at doses up to 0.78µg/kg;
  • Partial responses were reported in 3 of the first 6 patients dosed;
  • Best tumour response reported was a 44% reduction in the sum of target lesions measured;
  • Three (3) patients continued L-DOS47 monotherapy following induction therapy of L-DOS47 in combination with pemetrexed/carboplatin.

On July 25 th , 2017, the company announced that the Safety Review Committee ("SRC") reviewed safety data from the second dosing cohort and recommended that Helix begin enrollment of patients into the third dosing cohort of study LDOS001. Patients enrolled in the third dosing cohort will receive the next L-DOS47 dose level which is 1.50 micrograms of L-DOS47 per kilogram of patient body weight.

To-date, a total of 85 patients have received doses of L-DOS47 ranging from 0.12μg/kg to 13.55μg/kg in all completed and ongoing studies. Repeat administrations of L-DOS47 for doses up to 13.55µg/kg were safe and well tolerated. Adverse events reported from all completed and ongoing studies support an accelerated dose design of L-DOS47 in combination with standard of care pemetrexed/carboplatin.

About L-DOS47

L-DOS47 is Helix's first immunoconjugate based drug candidate in development based on the Company's novel, proprietary DOS47 platform technology, which is designed to use an innovative approach to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction.

About L-DOS47 clinical development

L-DOS47 is currently being clinically evaluated in two clinical studies, in the United States and Poland and, as a treatment for certain patients with non-small cell lung cancer ("NSCLC").

LDOS001 is a Phase I, open-label, dose escalation study being conducted in the United States at two centers: The University of Texas, M.D. Anderson Cancer Centre and University Hospitals Case Medical Center. The primary objective of the study is to determine the safety and tolerability of L-DOS47 in combination treatment with pemetrexed/carboplatin. The study will also evaluate the potential clinical benefit of L-DOS47 with this combination.

LDOS002 is an open-label Phase I/II clinical study being conducted in Poland to evaluate the safety, tolerability and preliminary efficacy of ascending doses of L-DOS47, initially as a monotherapy, in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous, stage IIIb/IV NSCLC.

About Helix BioPharma Corp.

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Cautionary Statements

This news release may contain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws including, without limitation, those relating to Helix's operations and strategy and its research and development activities. These statements generally can be identified by forward looking words such as "accelerate", "significant", "achievement", "advancement", "rapidly", "best", "further", "ongoing", "excited", "efforts", "will" or "modify", and other similar expressions, are intended to provide information about management's current plans and expectations.

Forward-looking statements include, without limitation, statements concerning (i) the Company's ability to operate on a going concern being dependent mainly on obtaining additional financing; (ii) the Company's priority continuing to be L-DOS47; (iii) the Company's development programs for DOS47 and L-DOS47; (iv) future expenditures, the insufficiency of the Company's current cash resources and the need for financing; and (v) future financing requirements and the seeking of additional funding. Forward-looking statements can further be identified by the use of forward-looking terminology such as "ongoing", "estimates", "expects", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", or "should" occur or be achieved, or comparable terminology referring to future events or results.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, risks inherent in Helix's research and development activities and those risks and uncertainties affecting the Company, as more fully described in Helix's most recent Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors, estimates or assumptions have been applied in making forward-looking statements including, without limitation, the safety and efficacy of the Company's drug product candidates; that sufficient financing will be obtained in a timely manner to allow the Company to continue operations and implement its clinical trials in the manner and on the timelines anticipated; the timely provision of services and supplies or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans; the timely receipt of required regulatory approvals and strategic partner support and that the factors described in the Helix Risk Factors will not cause the Company's actual results or events to differ materially from the forward-looking statements. These cautionary statements qualify all such forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions, opinions, plans and expectations of Helix's management on the date of this news release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions, plans or expectations, or other circumstances change, except as required by law.

Helix BioPharma Corp. Investor Relations 905 841 2300 905 841 2244 (FAX) ir@helixbiopharma.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 205

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 327

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 221

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 330

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 299

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 287

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 264

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

Elis Capital Structure Overview and Voting Rights Update

Updated Category News Views 292

Elis Capital Structure Overview Elis, a prominent player in the services sector, is committed to providing transparency regarding its capital structure. As of the recent assessment, the company detailed the number of shares that constitute its capital along with the total number of voting rights. Share Capital and Voting Rights According to French legal requirements,...

Continue Reading
A. Walker & Company Secures $50 Million for Housing Projects

Updated Category News Views 244

A. Walker & Company Secures Major Capital Commitments A. Walker & Co. recently secured a significant capital commitment totaling up to $75 million, including an initial $50 million specifically set aside for affordable housing development. This funding is a critical step towards increasing the availability of multifamily housing that can effectively serve the needs of...

Continue Reading
ClorDiSys Enhances Sterilization Capabilities with Expansion

Updated Category News Views 228

ClorDiSys Expands Sterilization Operations ClorDiSys Solutions, LLC has announced a significant expansion in its sterilization facilities, designed to address the growing demand for its chlorine dioxide-based sterilization services. This expansion includes the addition of new chambers, which will effectively double the company’s processing capacity. With the new...

Continue Reading
Star Equity's KBS Builders Secures Major Contracts Worth $5.2M

Updated Category News Views 173

KBS Builders Secures Significant Commercial Contracts Star Equity Holdings, Inc. is excited to announce that its subsidiary, KBS Builders, has successfully signed two major contracts worth a total of $5.2 million. These contracts focus on the manufacturing of housing units, promising to contribute positively not only to KBS's growth but also to addressing the ongoing...

Continue Reading
Navigating the Startup Jungle: Break Free from Traps

Updated Category News Views 158

Understanding the Existing Market Trap A fresh approach from the creators of Play Bigger reveals the hidden costs startups face. The new book titled The Existing Market Trap: A Primer presents a timely exploration into why many startups struggle to gain traction. Co-authors Al Ramadan, Christopher Lochhead, alongside new contributors Jason Wellcome and Mary Gr

Continue Reading